Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Nivolumab and ipilimumab for advanced BCVH

Bradley McGregor • 2 Jun 2019
ASCO 2019
Bladder Cancer Genitourinary Cancer Antibodies Ipilimumab Nivolumab

Bradley McGregor, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the Phase II study (NCT03333616) looking at nivolumab and ipilimumab for advanced bladder cancer of variant histologies (BCVH). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Bradley McGregor

4:21
Sacituzumab govitecan plus enfortumab vedotin for treatment of advanced urothelial cancer
Bradley McGregor • 22 Oct 2023
4:21
Sacituzumab govitecan plus enfortumab vedotin in advanced urothelial cancer
Bradley McGregor • 23 Oct 2023
2:09
Enfortumab vedotin for bladder cancer
Bradley McGregor • 2 Jun 2019
2:09
Cytoreductive nephrectomy in mRCC
Bradley McGregor • 2 Jun 2019

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals